Vivos (RDGL) Income from Continuing Operations (2010 - 2025)
Vivos' (RDGL) quarterly Income from Continuing Operations came in at -$1.1 million in Q4 2025, down 5.41% year-over-year from -$1.1 million in Q4 2024, and down 112.6% quarter-over-quarter from -$507294.0 in Q3 2025.
Powered by 
Analysis
Vivos (RDGL) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Vivos has disclosed Income from Continuing Operations across 16 years of filings, most recently posting -$1.1 million for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 5.41% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$3.1 million (down 5.35% YoY), while the FY2025 annual figure was -$3.1 million, down 5.35% from the prior year.
- Income from Continuing Operations came in at -$1.1 million for Q4 2025 at Vivos, down from -$507294.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of -$178230.0 in Q4 2021 to a low of -$1.9 million in Q2 2021.
- Average Income from Continuing Operations over 5 years is -$693457.2, with a median of -$683797.5 recorded in 2022.
- Year-over-year, Income from Continuing Operations slumped 1069.29% in 2021 and surged 64.52% in 2023.
- Over 5 years, Income from Continuing Operations stood at -$178230.0 in 2021, then sank by 295.92% to -$705653.0 in 2022, then tumbled by 52.51% to -$1.1 million in 2023, then grew by 4.93% to -$1.0 million in 2024, then retreated by 5.41% to -$1.1 million in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were -$1.1 million in Q4 2025, -$507294.0 in Q3 2025, and -$645513.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Vivos | 23.21 Mn | 23.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -507,294.00 |
| Jun 30, 2025 | -645,513.00 |
| Mar 31, 2025 | -834,696.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -825,263.00 |
| Jun 30, 2024 | -503,458.00 |
| Mar 31, 2024 | -558,539.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -667,690.00 |
| Jun 30, 2023 | -902,526.00 |
| Mar 31, 2023 | -248,318.00 |
| Dec 31, 2022 | -705,653.00 |
| Sep 30, 2022 | -277,065.00 |
| Jun 30, 2022 | -787,538.00 |
| Mar 31, 2022 | -699,905.00 |
| Dec 31, 2021 | -178,230.00 |
| Sep 30, 2021 | -201,160.00 |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -288,189.00 |